Seattle Genetics is propped at the top of the apex as one of the premier cancer-fighting organization in modern-day society. This particular organization is located in Bothell, Washington, and it employs over 900 individuals. Yes, this is 100 percent accurate. The organization has been around for two decades, and it is now worth an estimated $10 billion. Just over the last few years, the organization’s stock has actually tripled. It has a pipeline of advanced drugs that are waiting to be approved, but its flagship drug has gone on to save millions of lives. This drug is known as ADCETRIS, and it is now being used in over 60 different countries worldwide. So, how did this come about?
Seattle Genetics is actually the creation of Dr. Clay Siegall. This extraordinary man got together with a few of his closest associates and opened a new biotech-oncology company in the Pacific Northwest. Dr. Siegall has remained with the company through the thick and thin. He is now one of the most respected individuals in the game because he brings so much to the table. One of the biggest reasons for the organization’s success is via principles. Dr. Siegall has embedded his three core principles of drug development, scientific innovation and rigorous research right into the program. Being such an “old-guard” of the game, he has provided copious amounts of research and data on each advanced medication.
The older chemotherapy treatments have become a relic to some degree. These medications can literally hurt the patient more so than help the patient. Dr. Siegall started his mission to find more efficient cancer treatments after the death of his father. He has earned multiple degrees, has written up to 70 cancer-related publications and has at least 15 patents under his belt. This only scratches the surface to what this man has achieved, and it will not be the end of what he has set out to do.